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editorial
ESMO clinical recommendations: a
practical guide for medical
oncologists
During the last two decades different clinical practice guidelines
(CPGs) have been developed by various panels of experts.
The major goals of CPGs are: (a) to serve as a guide by
practitioners for appropriate clinical decision-making; (b) to
improve the quality of health care and outcomes for patients;
and (c) to support and influence regional or national
authorities when deciding the allocation of resources. As
Eisenberg points out, ‘one simple definition of quality in
healthcare is providing the right care, at the right time, for
the right person in the right way’ [1].
Producers of CPGs are based on the evidence-based
medicine (EBM) system. EBM was first established in 1992
as a more scientific and systematic approach to the practice
of medicine: ‘EBM is consider as the process of systematically
finding, appraising and using contemporaneous research findings
as the basis for clinical decisions. EBM is about asking questions,
finding and appraising the relevant data, and harnessing
information for everyday clinical practice’ (Table 1) [2–4].
In a recent systematic review of clinicians’ attitudes to clinical
practice guidelines, 30 studies from 1990 to 2000 were analysed.
Guidelines were focused on various medical or surgical topics
and originated from Europe, the United States, Canada and
Australia. Results showed that 70–75% of clinicians agreed
that guidelines were useful sources of advice, good educational
tools and intended to improve quality in healthcare. In
contrast, 30–53% of them also considered the guidelines to be
impractical and too rigid to apply to individual patients as
they might reduce doctors’ autonomy, oversimplify medicine
and pave the way for litigation. In addition they might prohibit
potential benefits for patients, as they might be intended to
cut healthcare costs [5].
There is increasing concern about variation in guideline
quality due to methodological problems, setting of criteria,
priorities and so on. Recently Vigna-Taglianti et al. reported
that the quality of approximately one-half of the systematic
reviews used in guidelines for oncology practice is poor: 29%
of them do not match the definition of systematic review and
21% follow unclear methodology. Four ESMO clinical
recommendations for breast and colorectal cancer were also
included in this analysis, indicating a similar weakness [6].
Over the years it has become evident that guidelines should
be clearer about the context of their development and the
methodology utilized. This is essential in order to improve
the quality of guidelines and to encourage their use in daily
clinical practice [7, 8].
A large number of organizations have developed practice
guidelines in oncology at a national, regional or local level,
including federal agencies, medical societies or other scientific
groups. From international assessments of the quality of
clinical practice guidelines, it has been shown that oncology
Table 1. Evidence-based medicine systems
Type of system Description
Type C basis (general consensus) There is a widespread consolidated consensus. Randomized trials have not been carried out or
have been inadequate, but the issue is settled without major controversy; currently, no
(further) experimental evidence is felt to be needed.
Type 1 evidence (randomized trial/s
available, strong evidence)
Consistent results have been provided by more than one randomized trial, and/or a reliable
meta-analysis was performed. In some instances, one randomized trial can be considered
sufficient to support this type of evidence. Further confirmatory trials do not seem necessary.
Type 2 evidence (randomized trial/s
available, weak evidence)
One or more randomized trials have been completed, but the evidence they provide is not
considered definitive (their results are not consistent, and/or they are methodologically
unsatisfactory, etc.). Some controlled evidence has therefore been provided, but confirmatory
trials would be desirable.
Type 3 evidence (external controlled
comparisons available)
Evidence is available from non-randomized studies, with external controls allowing comparisons.
Some uncontrolled evidence has therefore been provided, but trials would be desirable.
Type R basis (rational inference) Little or no direct evidence from clinical studies is available. Yet clinical conclusions can be
rationally inferred from available data and knowledge (by rationally combining pieces of
information from published studies and observations; e.g. for a rare neoplasm or presentation,
through analogy with a related, more common tumour or presentation). The inference can be
more or less strong, and trials may or may not be desirable (although sometimes unfeasible).
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guidelines had significantly higher scores than non-oncology
guidelines. From an assessment of the quality of 100 guidelines,
including 32 oncology guidelines, using the Appraisal of
Guidelines and Research and Evaluation (AGREE) Instrument,
oncology guidelines seem to be of better quality than others
(42.2% vs 29.4%; P = 0.02) [9].
In a national survey of Canadian oncologists’ attitudes
towards practice guidelines, over 80% of the respondents
agreed that they were good educational tools, convenient
sources of advice and intended to improve quality of care.
Conversely, 42% felt that they were intended to cut costs,
26% that they were oversimplified ‘cookbook’ medicine,
20% that they were too rigid to apply to individual patients
and 16% that they were a challenge to the physician’s
authority. Nevertheless, Canadian oncologists were quite
positive about practice guidelines and reported using them
frequently [10, 11].
In another study 1500 members of the American Society
of Clinical Oncology (ASCO) were queried about (a) whether
they had read the ASCO guidelines; (b) whether they agreed
with the recommendations; (c) whether they used guidelines
in clinical practice; and (d) how guidelines had affected
reimbursement. It was found that ASCO guidelines were
generally highly supported by physicians. Although they are
read more often by oncologists in private practice, 25% of
respondents reported that guidelines were difficult to apply to
daily practice and 10% indicated that the guidelines were
difficult to evaluate, interpret or read [12].
ESMO clinical recommendations
The European Society for Medical Oncology (ESMO) has
developed and disseminated clinical recommendations to all
European and non-European oncologists. ESMO’s motivation
was to establish the clinical recommendations, as it was felt they
were important for the future development of medical
oncology and for achieving high common standards of medical
practice for patients in all European countries.
The original idea for the creation of the ESMO clinical
guidelines came from Professor Heine H. Hansen via the
Central European Task Force in 1998. In particular, he
visualized the need for clinical recommendations that might
be more practical in daily use. This was supported at a meeting
of the ESMO national representatives, who felt that the
development of guidelines would contribute to the standing
of medical oncology in Europe.
Thus, in 1999 the ESMO Guidelines Task Force was
constituted. Initially, the group began with a chairman
(Rolf Stahel, Switzerland), a central coordinator (Lorez Jost,
Switzerland), an ESMO officer (Maria Cristina Reinhart) and
five members (Jørn Herrstedt, Denmark; Otto Kloke, Germany;
Nicholas Pavlidis, Greece; Gunta Purkalne, Latvia; and
Svetislav Jelic, Yugoslavia). During the next 5 years more
members joined the task force (Jonas Bergh, Sweden; Richard
Greil, Austria; Vesa Kataja, Finland; and Joa˜o Olivera,
Portugal).
The clinical recommendations are an important expression
of ESMO’s mission to disseminate knowledge in order to
maintain a high common standard in medical practice for
cancer patients. First, the guidelines are a tool for clinicians
to help them offer the best care to their patients on a daily basis.
They also help support negotiations with politicians,
administrators and insurance companies regarding the level of
care that should be made available. The principles of the ESMO
clinical recommendations were: (a) to create a set of statements
for an essential standard of care in no more than three pages;
(b) to be disease- or topic-oriented; (c) to be evidence-based;
(d) to have an emphasis on medical oncology; and (e) to be
regularly updated.
Each of the ESMO clinical recommendations provides
vital, evidence-based information for physicians, including
the incidence of the malignancy, diagnostic criteria, staging
of disease and risk assessment, treatment plans and
follow-up.
Since 1 January 2006 the Guidelines Task Force has been an
independent group—the ESMO Guidelines Working
Group—under the new ESMO Education Committee
structure. It consists: (1) of an editorial board with a chairman
(Nicholas Pavlidis, Greece), three members (Rolf Stahel,
Switzerland; Heine Hansen, Denmark; and Svetislav Jelic,
Serbia), an Annals of Oncology executive (Lewis Rowett, UK)
and an ESMO Officer (Paola Minotti, Switzerland), (2) of
the seven subject editors responsible for the topics, the
authors, the revision of the manuscripts and the presentation
and discussion of final drafts with the editorial board
(M. Castiglione, Switzerland; J. Oliveira, Portugal; E. Felip,
Spain; V. Kataja, Finland; M. Dreyling, Germany; L. Jost,
Switzerland; and F. Roila, Italy), (3) of the assigned authors
and (4) of the five preselected reviewers per topic have all been
ESMO faculty members (Figure 1).
Nearly 7 years after the inception of the ESMO Guidelines
Task Force and up to the end of 2006, 39 clinical
recommendations were freely available on the ESMO website
[13] and in Annals of Oncology. The future intention is to cover
not only most of the malignant tumours, but also other topics
in oncology.
The current activities of the ESMO Guidelines Working
Group include: (a) generation of yearly updates and new
guidelines through an online process; (b) yearly publication of
ESMO clinical recommendations as supplements to Annals of
Oncology; (c) interactive guideline sessions at ESMO
congresses; and (d) promotion of ESMO clinical
recommendations.
In a Letter to the Editor in 2002, Fervers et al. criticized
ESMO clinical recommendations concerning their strategy
and quality as well as their ability to influence oncology
practice [14]. Our answer to this criticism is that the ESMO
clinical recommendations are built on a philosophy of
providing basic and practical information to oncologists
and protecting them from ‘what and how not to do things’.
The formulation of ESMO clinical recommendations is
always made according to the principles of evidence-based
medicine and, according to the new structure of the working
group, every single clinical recommendation is assigned to
a specific subject editor, is written by an expert author and is
reviewed by five independent multidisciplinary external
reviewers.
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dissemination and implementation of
ESMO clinical recommendations
Three different methodological tools were used in order to
evaluate the spectrum of dissemination and implementation of
ESMO clinical recommendations. The first was the evaluation
scoring from the interactive guidelines sessions at ESMO
congresses. The second was a survey/questionnaire given
during the 31st ESMO Congress. This questionnaire
had been designed by Johns Hopkins University, Baltimore,
in 1994 and mailed to members of the American College of
Physicians (ACP) to assess their familiarity, confidence and
attitudes relating to guidelines issued by the ACP [15]. The
third tool was the extraction of 12 months’ data from
downloads of Oxford Journals usage statistics through the
supplementary issue of Annals of Oncology in which the 2005
ESMO guidelines were published [16].
results from the evaluation of the ESMO
guidelines sessions
The last four (2000–2006) ESMO congresses conducted 2-hour
interactive sessions on ESMO guidelines, where different
cases with various tumours were presented and discussed,
based on the ESMO clinical recommendations. The average
evaluation scoring of all sessions is shown in Table 2. It is
apparent that over the years this activity has been getting
a steadily higher recognition from the European as well as
the international oncological community.
results from the questionnaire
During the 31st ESMO Congress in Istanbul in 2006 an
interactive session with six case presentations was held.
Both at the onset as well as at the closure of the session, the
audience was asked to answer ten questions through an
electronic voting system (Table 3). The first three questions,
asked at the onset, were related to audience exposure to
ESMO clinical recommendations, while the seven questions
asked at the end of the session were taken from the survey
of Tunis et al. [15]. At the beginning more than 600
participants answered. Among them 61.1% were medical
oncologists, 12.4% clinical oncologists, 6.1% radiation
oncologists and 4.6% surgical oncologists, and the rest (15.7%)
belonged to various other specialties.
From the analysis of the questionnaire it was encouraging to
see that half of the attendees had consulted ESMO clinical
recommendations over the last year and one-third had
consulted them more than once. Several factors might
contribute to the fact that half of the attendees had not yet
consulted ESMO clinical recommendations. It could be that
some attendees at the ESMO Congress were not ESMO
members; some might not have been aware of the guidelines;
also, more young oncologists are attending the interactive
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Figure 1. The new structure of the ESMO Guidelines working group.
Table 2. Evaluation of ESMO interactive guideline sessions
Date and place of
congress
Subjects discussed Average
scorea
2000, Hamburg Colon cancer 3.78
Non-small cell lung
cancer
Testicular cancer
2002, Nice Cancer of unknown
primary
4.05
Ovarian cancer
Prostate cancer
2004, Vienna Breast cancer
(metastatic)
4.07
Follicular lymphoma
Rectal cancer
2006, Istanbul Breast cancer
(adjuvant)
4.24
Non-small cell lung
cancer
Hodgkin’s lymphoma
aOn a scale of 1 to 5.
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sessions every year. More than 60% of the attendees preferred
to have access to ESMO clinical recommendations through the
ESMO website.
More than 80% of the respondents felt that ESMO clinical
recommendations were a helpful source of advice and 85%
believed that they were a good educational tool. Almost all
attendees (95%) thought that ESMO clinical recommendations
were intended to improve patients’ quality of care, 40% did
not agree that they were intended to cut health care costs
and 41% thought they would increase litigation or disciplinary
action. It is important to notice also that 75% of respondents
did not support the notion that ESMO clinical
recommendations reduced physicians’ autonomy and almost
82% did not believe that they were too rigid or impractical
to be used. Taken together, the results of this inquiry are
in keep with the results of the systematic review of Farquhar
et al. [5].
results from annals of oncology downloads
When we extracted data from the downloads of Oxford
Journals usage statistics through the 2005 supplementary
issue of Annals of Oncology [14] from 1 January 2006 to
31 December 2006, a total of 66831 downloads were detected.
The three most commonly downloaded tumour-related
topics were ‘primary breast cancer’ (4707 downloads),
‘primary colon cancer’ (3395 downloads) and ‘metastatic
breast cancer’ (3089 downloads), while the three least
commonly downloaded topics were ‘relapsed large-cell NHL’
(1355 downloads), ‘osteosarcoma’ (1251 downloads) and
‘Ewing’s sarcoma’ (1247 downloads).
perspectives
Supporting a wide spectrum of cancer doctors (i.e.,
practitioners or hospital physicians) with the ESMO clinical
recommendations remains our first priority. The ESMO
Guidelines Working Group feels that the clinical
recommendations have been successfully recognized by
European and non-European oncologists. The simple format
and yearly updates of the ESMO clinical recommendations
and the free access via the internet have probably contributed
to this. In addition, the ESMO Guidelines Working Group
will continue to present yearly updates, and it is also planning
to develop 17 additional guidelines over the next 2 years,
including guidelines on several rare cancers. We intend also to
keep the interactive guidelines session at every ESMO congress.
It is important to notice that the ESMO guidelines have
already been translated into several languages (French, German,
Italian, Spanish, Portuguese, Russian, Japanese and Chinese)
and the working group will continue to encourage such efforts.
Another task of the working group is to disseminate ESMO
guidelines to any scientific or educational institution in Europe.
Also, placing reports and publications in various newsletters
or journals and participating in lectures at various oncology
meetings will be strongly emphasized.
ESMO guidelines are not competing with other national
or international guidelines but are complementary
recommendations to other existing guidelines. Our ultimate
goal is to provide practical, annually updated basic
recommendations covering all tumour types and our vision
is to ensure that ESMO guidelines are introduced and
continue to be used in day-to-day practice.
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Table 3. Analysis of the audience questionnaire administered during the
31st ESMO Congress, Istanbul 2006
Question Responses Percentage
response
1. How many times have you
attended the ESMO CR
sessions during ESMO
congresses (2000–2006)?
Once 64.7% (417/641)
Twice 19.5% (125/641)
Three times 9.1% (58/641)
Four times 6.6% (43/641)
2. Within the last year how
many times have you
consulted the ESMO CRs?
Not at all 51.7% (333/644)
Once 15.1% (97/644)
<10 times 25.9% (167/644)
>10 times 7.3% (47/644)
3. What is your preferred
access to ESMO CRs?
Annals of Oncology 37.5% (250/666)
ESMO website 62.5% (416/666)
4. Do you think ESMO CRs
are a helpful source of
advice?
Yes 80.8% (143/177)
No 6.8% (12/177)
Don’t know/no
answer
12.4% (22/177)
5. Do you think ESMO CRs
are good educational tools?
Yes 84.9% (140/165)
No 7.9% (13/165)
Don’t know/no
answer
7.3% (12/165)
6. Do you think ESMO CRs
are intended to improve
quality of care?
Yes 94.8% (146/154)
No 1.3% (2/146)
Don’t know/no
answer
3.9% (6/146)
7. Do you think ESMO CRs
are intended to cut health
care costs?
Yes 32.9% (48/146)
No 40.4% (59/146)
Don’t know/no
answer
26.7% (39/146)
8. Do you think ESMO CRs
will increase litigation or
disciplinary action?
Yes 40.9% (61/149)
No 38.3% (57/149)
Don’t know/no
answer
20.8% (31/149)
9. Do you think ESMO CRs
reduce physicians’
autonomy and are
oversimplified or
‘cookbook’ medicine?
Yes 20.3% (30/148)
No 74.3% (110/148)
Don’t know/no
answer
5.4% (8/148)
10. Do you think ESMO CRs
are impractical and too
rigid to apply to individual
patients?
Yes 12.6% (18/143)
No 81.8% (117/143)
Don’t know/no
answer
5.6% (8/143)
CRs, clinical recommendations.
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